Rare tumors
Teams
-
Olivier Hermine
>> Research Lab
Molecular mechanisms of hematological disorders and therapeutic implications -
Sabine Sarnacki
>> Associated Lab
IMAG2 - Computational anatomy for image-guided minimally invasive surgery in pe… -
-
Christine Bodemer
>> Reference Center for rare diseases
Genetic skin disorders (MAGEC)
Associated with the French Healthcare Network FIMARAD and the European Reference Network (ENR) SKIN -
Dominique Brémond-Gignac
>> Reference Center for Rare Diseases
OPHTARA - Rare ophthalmological diseases -
Valérie Cormier-Daire
>> Reference center for rare diseases
Constitutional bone diseases (MOC)
Associated with the European Reference Network (ERN) BOND -
-
Olivier Hermine
>> Reference Center for rare diseases
Reference Center for Mastocytosis (CEREMAST)
Associated with the French Healthcare Network MARIH, the European Reference Network (ERN) EuroBloodnet and European Competence Network on Mastocytosis
Imagine's Offers
-
MastocytosisGenotype Phenotype
-
Cohorts
Pediatric and adult
>500
-
Observational trials
NCT02441166: diagnostic value of bone marrow tryptase in systemic Mastocytosis (EvaTryMS)
Prospective study on pediatric mastocytosis: long term follow up of 53 patients with whole sequencing of KIT
Multicenter retrospective French study on 53 patients with mastocytosis among elderly patients
-
Patient samples
Blood
Targets-
Specific targets
tyrosine kinase activity of KIT
TherapeuticsClinical trials-
NCT
NCT00814073: phase III Masitinib in severe indolent or smoldering systemic Mastocytosis (AB06006)
NCT03401060: phase III interest of Denosumab treatment in osteoporosis associated to systemic Mastocytosis (DenosuMast)
NCT01266369: phase II Masitinib in patients with mastocytosis with handicap and bearing the D816V mutation
NCT00831974: phase II efficacy of AB1010 in patients with systemic indolent Mastocytosis
NCT02478957: phase II treatment of indolent systemic Mastocytosis with PA101
Myelodysplastic syndrome (MDS)Genotype Phenotype-
Cohorts
Please, contact us
Targets-
In vivo models
Grafted mice (bone marrow, blasts)
Therapeutics-
Protocols/Technics
Tumor grafting in mice
Clinical trialsLeukemias
Acute Myeloid Leukemia (AML)Genotype Phenotype-
Cohorts
Cohort associated with GOELAMS
Please, contact us
-
Patient samples
Blasts derived from AML patients
Targets-
In vitro models
Human AML cell lines
-
In vivo models
Grafted mice (bone marrow, blasts)
-
Specific targets
GDF11
Therapeutics-
Protocols/Technics
Tumor grafting in mice
Clinical trialsAcute Lymphocytic Leukemia (ALL)Genotype Phenotype-
Cohorts
Please, contact us
-
Patient samples
Blasts derived from ALL patients
Targets-
In vitro models
Human ALL cell lines
-
In vivo models
Grafted mice (bone marrow, blasts)
Therapeutics-
Protocols/Technics
Tumor grafting in mice
Clinical trialsChronic Myeloid Leukemia (CML)Genotype Phenotype-
Cohorts
Please, contact us
-
Patient samples
Blasts derived from CML patients
Targets-
In vivo models
Grafted mice (bone marrow, blasts)
Therapeutics-
Protocols/Technics
Tumor grafting in mice
Clinical trialsChronic Lymphocytic Leukemia (CLL)Genotype Phenotype-
Cohorts
Please, contact us
-
Patient samples
Blasts derived from CLL patients
Targets-
In vivo models
Grafted mice (bone marrow, blasts)
Therapeutics-
Protocols/Technics
Tumor grafting in mice
Clinical trialsMast cell leukemiaGenotype Phenotype-
Cohorts
Please, contact us
-
Patient samples
Bone marrow
Targets-
In vivo models
Grafted mice (bone marrow, blasts)
Therapeutics-
Protocols/Technics
Tumor grafting in mice
Clinical trialsLymphomas
Mantle cell lymphomaGenotype Phenotype-
Cohorts
Please, contact us
-
Patient samples
Blasts derived from Mantle cell lymphoma patients
Targets-
In vitro models
Human Mantle cell lymphoma cell lines
-
In vivo models
Grafted mice (bone marrow, blasts)
Therapeutics-
Protocols/Technics
Tumor grafting in mice
Clinical trialsHTLV-1-associated adult T-cell leukemia/lymphomaGenotype Phenotype-
Cohorts
Please, contact us
TargetsTherapeuticsClinical trials -
Contacts
-
Erminia RUBINO
Business development manager
- erminia.rubino@institutimagine.org
- +33 1 42 75 46 65
